Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion. Over the last five years, shares have soared by more than 400%.Recently, however, the stock has been struggling; in the past three months, Lilly's valuation has declined by 21%. It fell last week after the company released updated guidance, with revenue for its GLP-1 drugs projected to come in below expectations for the most recent quarter.Is this a sign the stock is in trouble and likely headed for more of a decline this year? Or could now be a good time to buy Eli Lilly on the dip?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool